Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

Conclusion. Doripenem is an injectable carbapenem antibiotic with a spectrum of activity comparable to that of imipenem and meropenem. Its safety is similar to that of other carbapenems.

Antibiotics are overused by some and out of reach for others - fuelling resistance and leaving deadly gaps in care.

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

Drug makers Spero Therapeutics and GSK announced yesterday that a phase 3 trial evaluating their investigational oral ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Resistance to carbapenems in Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, mainly determined by the production of carbapenem-hydrolyzing β-lactamases, has emerged ...